Medication info

Treble Tablet 80/10/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›13.87mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
30 tablets (10 tablets x 3)/PTP
Approval status
Active

MFDS item code 201802588 · Approved 2018.06.20

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine should be taken once daily as 1 tablet with water, regardless of meals. It is recommended to take it at the same time each day, if possible (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin alone, they may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination It is recommended to adjust the dose using the individual components (amlodipine or telmisartan) before administering the telmisartan/amlodipine combination. However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is effective for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.4-fold and AUC increased approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk resulting from the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol level
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients with essential hypertension who have difficulty controlling blood pressure using a combination of telmisartan and amlodipine, and in cases where rosuvastatin needs to be used concurrently. The telmisartan/amlodipine combination is effective in treating hypertension in patients who do not respond well to monotherapy. Rosuvastatin is used as an adjunct in patients with hypercholesterolemia or combined dyslipidemia when diet and exercise are insufficient. It also helps delay the progression of atherosclerosis in patients with familial hypercholesterolemia and dysbetalipoproteinemia. Furthermore, it is used to reduce the risk of stroke, myocardial infarction, and risks related to arterial revascularization in patients at high cardiovascular risk. Therefore, this medication is used to improve cardiovascular health by managing both blood pressure and cholesterol levels.

How to take

Adult dose

This medicine should be taken once daily as 1 tablet with water, regardless of meals. It is recommended to take it at the same time each day, if possible (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin alone, they may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination It is recommended to adjust the dose using the individual components (amlodipine or telmisartan) before administering the telmisartan/amlodipine combination. However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is effective for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.4-fold and AUC increased approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk resulting from the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, and it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any ingredients in this medication or similar drugs, a history of angioedema, women who are pregnant or of childbearing potential, and patients with severe liver or kidney disease should not take this medication. In addition, patients with severe hypotension, the elderly, patients with hyperkalemia, patients with impaired liver function, and patients with cardiac disease or renovascular hypertension should use this medication with caution, and should consult a doctor immediately if muscle pain or myopathy symptoms occur. There is a risk of muscle damage with this medication, so regular monitoring of muscle enzymes (CK) and liver function tests before and during treatment is necessary. If symptoms such as muscle pain, muscle weakness, or cramps occur, treatment should be stopped immediately and medical attention sought. There may be low blood pressure or worsening kidney function, so special attention should be paid to patients with dehydration or kidney disease. While taking this medication, caution is needed as drowsiness or dizziness may occur when driving or operating dangerous machinery. Additionally, this medication may interact with other drugs, so patients should inform their doctor or pharmacist about any other medications they are taking. Women who are pregnant or breastfeeding should not take this medication, and women of childbearing potential should use appropriate contraceptive methods. This medication is not recommended for children under 18 years of age, as safety and efficacy have not been sufficiently demonstrated. In case of overdose, symptoms such as hypotension, dizziness, and irregular heartbeat may occur, and immediate medical attention should be sought. This medication should be stored out of the reach of children, and it is advisable not to transfer it to another container.

Side effects

Viral upper respiratory tract infection, dyspnea, anal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, hiatal hernia, dysuria, rhinitis, oropharyngeal discomfort, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, headache, dizziness, orthostatic hypotension, back pain, edema, flushing, palpitations, fatigue, nausea, abdominal pain, drowsiness, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, vasculitis, peripheral neuropathy, sensory abnormalities, tremors, vertigo, loss of appetite, constipation, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia, allergic reactions, back pain, burning sensation, malaise, pain, stiffness, weight gain, weight loss, arthralgia, arthritis, muscle cramps, myalgia, erectile dysfunction, insomnia, neuroplasticity, depression, abnormal dreams, anxiety, depersonalization, dyspnea, epistaxis, angioedema, erythema multiforme, pruritus, rash, erythematous rash, papulovesicular rash, visual disturbances, conjunctivitis, diplopia, ocular pain, ear pain, frequent urination, dysuria, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, headache, myasthenia, cough, weakness, facial edema, lower limb edema, angioedema, hypersensitivity reactions, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, increased blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, urinary tract infection, erectile dysfunction, back pain, abdominal pain, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, liver dysfunction, liver disease, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain, angioedema, angioedema, hypersensitivity reactions, diabetes, headache, dizziness, constipation, nausea, abdominal pain, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, headache, dizziness, orthostatic hypotension, back pain, edema, flushing, palpitations, fatigue, nausea, abdominal pain, drowsiness, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, vasculitis, peripheral neuropathy, sensory abnormalities, tremors, vertigo, loss of appetite, constipation, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia, allergic reactions, back pain, burning sensation, malaise, pain, stiffness, weight gain, weight loss, arthralgia, arthritis, muscle cramps, myalgia, erectile dysfunction, insomnia, neuroplasticity, depression, abnormal dreams, anxiety, depersonalization, dyspnea, epistaxis, angioedema, erythema multiforme, pruritus, rash, erythematous rash, papulovesicular rash, visual disturbances, conjunctivitis, diplopia, ocular pain, tinnitus, ear pain, frequent urination, dysuria, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, decreased memory, forgetfulness, amnesia, memory impairment, confusion

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a container that protects it from light, as it may be light-sensitive. Additionally, it is important to store it at room temperature, between 1 to 30 degrees Celsius, to maintain its efficacy and safety.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

30 tablets (10 tablets x 3)/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.